Artiva Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $232.14M
- P/E (TTM)
- –
- Dividend yield
- –
About Artiva Biotherapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops natural killer cell therapies to treat autoimmune disorders. The company’s primary candidate is AlloNK, an investigational allogeneic natural killer cell therapy currently undergoing clinical development. This lead candidate targets diseases including lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjögren’s disease, and idiopathic inflammatory myopathies. Artiva also maintains early-stage discovery and preclinical programs, as well as collaborative partnerships. Because all assets remain in development, the company has no commercialized products or paying customers, directing its therapies toward patients suffering from autoimmune diseases.
The company maintains its corporate headquarters and principal executive offices in San Diego, California. Its domestic presence includes a manufacturing facility located in San Diego. Artiva conducts its research, operational, and clinical trial activities in the United States without maintaining commercial facilities or global retail branches.
Summary of the business section of Artiva Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Artiva Biotherapeutics, Inc.
- Founded
- 2019
- Headquarters
- San Diego, CA
- Address
- 5505 Morehouse Drive 92121
- Phone
- (858) 267-4467
- Employees
- 104, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ARTV
- Exchange
- Nasdaq
- IPO date
- Jul 19, 2024
- Shares outstanding
- 49M, Jul 31, 2026
- Public float
- $15.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1817241
- CUSIP
- 04317A107
- ISIN
- US04317A1079
- EIN
- 86-3614316
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Fred Aslan | Chief Executive Officer, Director | 1,604,765 |
| Jennifer Bush | COO, CLO, Compliance Officer | 374,529 |
| Christopher Horan | Chief Tech Operations Officer | 323,084 |
| Gines Diego Miralles | President & Head of R&D | 122,500 |
| Subhashis Banerjee | Chief Medical Officer | 170,947 |
| Heather Raymon | SVP, Research and Development | 148,228 |
| Thad Allen Huston | Chief Financial Officer | 220,000 |
| Neha Krishnamohan | Chief Financial Officer | 99,356 |
| Thorsten Graef | Chief Medical Officer | 80,000 |
| Capital Healthcare Fund LP RA | Director | 17,329,570 |
| Alison Moore | Director | – |
| Elaine K. Sorg | Director | – |
| Brian Daniels | Director | – |
| Rajeev M. Shah | Director | 16,817,573 |
| RA Capital Nexus Fund III, L.P. | Director | 17,283,802 |
| Peter Kolchinsky | Director | 17,242,483 |
| RA Capital Nexus Fund, L.P. | Director | 16,817,543 |
| Ra Capital Management, L.P. | Director | 16,795,919 |
| Daniel G. Baker | Director | – |
| Laura Stoppel | Director | – |
| Elizabeth L. Hougen | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 104 full-time employees, 21 of whom held an M.D., Pharm.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |